Fulgent Genetics Expands Reach with Two Big Buys

Fulgent Genetics is making a big move in the lab world. They're buying two companies, Bako Diagnostics and StrataDx, for a cool $55. 5 million. This deal is expected to close in the first half of 2026, but only if all the necessary approvals come through. Fulgent is known for its tech-based approach to lab services and drug development. With this acquisition, they're adding more tests and experts to their team. Bako brings a wide range of pathology services, while StrataDx specializes in skin-related tests. Both companies are certified and accredited, which means they meet high standards in their field.Fulgent isn't just growing by buying other companies. They're also investing in artificial intelligence and digital tools to make their services faster and better. With these new additions, Fulgent plans to offer more services and reach more customers across the country. The CEO of Fulgent, Ming Hsieh, is excited about this deal. He believes it will help Fulgent grow even faster and offer better services. The CEOs of Bako and StrataDx are also happy about the merger. They think it will help them serve their clients better. This deal is a big step for Fulgent. It shows they're serious about expanding and improving their services. But like any big move, it comes with risks. There's no guarantee the deal will go through, and even if it does, there's no guarantee it will be a success.